In the past several years, China's domestic pharmaceutical consumption has increased dramatically. Pharmaceutical industry sales revenue has grown an average of 21.4 percent annually. Driven by strong economic growth, increasing urbanization and the health demands of an aging population, China's pharmaceutical market is projected to become one of the world’s largest. By 2020, China is expected to grow its pharmaceutical market volume to $220 billion USD, becoming the second-largest market after the United States.
Deloitte China Life Sciences practice
As a member of the Deloitte Global Life Sciences Industry network, Deloitte China Life Sciences Industry practice works closely with our global counterparts to provide industry players in pharmaceuticals, biotechnology, medical devices, pharmaceutical distribution and CRO with full and feasible solutions with new thinking leveraging our global industry's best practices as well as our knowledge and rich experience in the local market.
- Pharmaceutical R&D Trends in China: Opportunity and Influence for Localized Development
This report delves into the current status as well as future trends of China pharmaceutical R&D industry, and explains the strategic implications for multinational pharmaceutical companies, who should consider more localized R&D approaches to address new opportunities and challenges.
- 2015 Global life sciences sector outlook
The report outlines some of the top issues facing the global life sciences sector, provides a snapshot of activity in a number of geographic markets, and suggests considerations for companies as they seek to grow revenue and market share in 2015 and beyond.
- Healthcare and life sciences predictions 2020
The report is based on an observation of trends, events and bold steps that, if accelerated over the next five years and beyond, will paint a picture of a very different world.
- Transforming medical affairs in China
Rethinking the role and effectiveness of the Medical Affairs function has become an urgent priority for pharmaceutical companies in China. The report presents our perspective on these challenges and how they can be successfully overcome.